JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Spire Healthcare Group (LON:SPI - Free Report) in a report published on Thursday morning, MarketBeat.com reports. JPMorgan Chase & Co. currently has a GBX 344 ($4.28) price target on the stock.
Separately, Berenberg Bank lifted their target price on shares of Spire Healthcare Group from GBX 286 ($3.56) to GBX 300 ($3.73) and gave the stock a buy rating in a report on Wednesday.
Read Our Latest Stock Report on Spire Healthcare Group
Spire Healthcare Group Stock Up 4.0 %
SPI traded up GBX 9.50 ($0.12) during trading on Thursday, hitting GBX 248 ($3.09). The company had a trading volume of 2,573,226 shares, compared to its average volume of 454,168. The company has a market capitalization of £1.00 billion, a PE ratio of 3,514.29, a PEG ratio of 1.06 and a beta of 0.99. Spire Healthcare Group has a one year low of GBX 204 ($2.54) and a one year high of GBX 321.71 ($4.00). The firm's 50-day moving average price is GBX 237.41 and its 200 day moving average price is GBX 228.84. The company has a quick ratio of 0.74, a current ratio of 0.69 and a debt-to-equity ratio of 170.37.
Spire Healthcare Group Increases Dividend
The firm also recently disclosed a dividend, which will be paid on Friday, June 21st. Shareholders of record on Thursday, May 23rd will be issued a GBX 2.10 ($0.03) dividend. The ex-dividend date is Thursday, May 23rd. This represents a yield of 0.89%. This is an increase from Spire Healthcare Group's previous dividend of $0.50. Spire Healthcare Group's payout ratio is currently 4,285.71%.
About Spire Healthcare Group
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Featured Articles
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
